Filing Flows › Health Care › InspireMD (NSPR)
InspireMD (NSPR) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · InspireMD (NSPR) Q2 2026 earnings results →
Q2 2026 Revenue down 0% year over year to $1.8M · 809¢ of every $1 of revenue lost · operating margin -815.6%
InspireMD made $1.8M in Q2 2026 (-0.4% Y/Y). Operating margin -815.6%, net loss $14.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.8M in Q2 2026, roughly flat year over year and down 48% from the previous quarter.
Operating costs exceeded revenue by $14.4M, an operating margin of -815.6%. The fastest-growing cost line was Sales & marketing (+25%). The quarter ended with a net loss of $14.3M, wider than the previous quarter's $13.7M loss.
Operating cash flow was −$10.9M. Non-cash charges added back $158K of depreciation and $2.2M of share-based compensation. Working capital and other items added $1.1M. Capital expenditures of $330K exceeded it, leaving free cash flow of −$11.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $1.8M | -0.4% | -815.6% | −$14.3M | −$10.9M |
| Q1 2026 | 10-Q | May 7, 2026 | $3.4M | +122% | -411.4% | −$13.7M | −$12.3M |
| Q4 2025 | 10-K | Mar 18, 2026 | $3.1M | +62% | -383.7% | −$11.8M | −$9.3M |
| Q3 2025 | 10-Q | Nov 10, 2025 | $2.5M | +39% | -517.3% | −$12.7M | −$8.6M |
| Q2 2025 | 10-Q | Aug 4, 2025 | $1.8M | +2% | -732.2% | −$13.2M | −$8.3M |
| Q1 2025 | 10-Q | May 8, 2025 | $1.5M | +1% | -749.5% | −$11.2M | −$8.8M |
| Q4 2024 | 10-K | Mar 12, 2025 | $1.9M | +11% | -480.6% | −$9.2M | −$6.8M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About InspireMD
We are a medical device company specializing in the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions. Our portfolio includes two commercial products based on our proprietary CGuard carotid stent technology, designed to provide market-leading embolic protection during and after stenting procedures. A stent is an expandable scaffold-like metallic device placed in an artery to widen the lumen and restore blood flow. Our first product, the CGuard Carotid Embolic Prevention System (“CGuard EPS”), integrates a self-expanding nitinol stent with a MicroNet mesh sleeve as a single device for carotid artery revascularization. In January 2024, we received CE Mark recertification for CGuard EPS under the EU Medical Device Regulation (“MDR”).
In its own words, from its 10-K, filed Mar 18, 2026.
InspireMD against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -0.4% against the peers' median +5%. Operating margin: -815.6% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| NSPR InspireMD | Q2 2026 | $1.8M | -0.4% | -815.6% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: InspireMD 10-Q on SEC EDGAR · CIK 1433607 · Surgical & Medical Instruments & Apparatus
13F: who owns NSPR and who is buying
More on NSPR
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results